Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Debt (2023 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Total Debt for 3 consecutive years, with $220.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 5.07% year-over-year to $220.3 million, compared with a TTM value of $220.3 million through Dec 2025, down 5.07%, and an annual FY2025 reading of $220.3 million, down 5.07% over the prior year.
  • Total Debt was $220.3 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $219.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $232.1 million in Q4 2024 and bottomed at $420000.0 in Q2 2024.
  • Average Total Debt over 3 years is $114.7 million, with a median of $104.2 million recorded in 2023.
  • The sharpest move saw Total Debt plummeted 97.48% in 2024, then surged 51953.81% in 2025.
  • Year by year, Total Debt stood at $190.9 million in 2023, then rose by 21.57% to $232.1 million in 2024, then dropped by 5.07% to $220.3 million in 2025.
  • Business Quant data shows Total Debt for XERS at $220.3 million in Q4 2025, $219.5 million in Q3 2025, and $218.6 million in Q2 2025.